Santoni M.; Massari F., mTOR Pathway in Renal Cell Carcinoma, «Molecules to Medicine with mTOR. Translating Critical Pathways Into Novel Therapeutic Strategies», 2016, 1, pp. 417 - 428 [Scientific article]
Ciccarese C.; Alfieri S.; Santoni M.; Santini D.; Brunelli M.; Bergamini C.; Licitra L.; Montironi R.; Tortora G.; Massari F., New toxicity profile for novel immunotherapy agents: Focus on immune-checkpoint inhibitors, «EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY», 2016, 12, pp. 57 - 74 [Scientific article]
Conteduca V.; Crabb S.J.; Jones R.J.; Caffo O.; Elliott T.; Scarpi E.; Fabbri P.; Derosa L.; Massari F.; Numico G.; Zarif S.; Hanna C.; Maines F.; Joyce H.; Lolli C.; De Giorgi U., Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer, «PLOS ONE», 2016, 11, Article number: e0158952 , pp. 1 - 12 [Scientific article]
Minardi D.; Mazzucchelli R.; Scarpelli M.; Massari F.; Ciccarese C.; Lopez-Beltran A.; Cheng L.; Montironi R., Prostate cancer glands with cribriform architecture and with glomeruloid features should be considered as Gleason pattern 4 and not pattern 3, «FUTURE ONCOLOGY», 2016, 12, pp. 1431 - 1433 [Scientific article]
Santini D.; Santoni M.; Conti A.; Procopio G.; Verzoni E.; Galli L.; di Lorenzo G.; De Giorgi U.; De Lisi D.; Nicodemo M.; Maruzzo M.; Massari F.; Buti S.; Altobelli E.; Biasco E.; Ricotta R.; Porta C.; Vincenzi B.; Papalia R.; Marchetti P.; Burattini L.; Berardi R.; Muto G.; Montironi R.; Cascinu S.; Tonini G., Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma, «ONCOTARGET», 2016, 7, pp. 33381 - 33390 [Scientific article]
Maines F.; Caffo O.; De Giorgi U.; Fratino L.; Lo Re G.; Zagonel V.; D'Angelo A.; Donini M.; Verderame F.; Ratta R.; Procopio G.; Campadelli E.; Massari F.; Gasparro D.; Ermacora P.; Messina C.; Giordano M.; Alesini D.; Basso U.; Fraccon A.P.; Vicario G.; Conteduca V.; Galligioni E., Safety and Clinical Outcomes of Abiraterone Acetate after Docetaxel in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme, «CLINICAL GENITOURINARY CANCER», 2016, 14, pp. 48 - 55 [Scientific article]
Lolli C.; Caffo O.; Scarpi E.; Aieta M.; Conteduca V.; Maines F.; Bianchi E.; Massari F.; Veccia A.; Chiuri V.E.; Facchini G.; De Giorgi U., Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone, «FRONTIERS IN PHARMACOLOGY», 2016, 7, Article number: 376 , pp. 1 - 7 [Scientific article]
Lolli C.; Basso U.; Derosa L.; Scarpi E.; Sava T.; Santoni M.; Crabb S.J.; Massari F.; Aieta M.; Conteduca V.; Maruzzo M.; La Russa F.; Wheater M.; Berardi R.; Galli L.; De Giorgi U., Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib, «ONCOTARGET», 2016, 7, pp. 54564 - 54571 [Scientific article]
Modena A.; Massari F.; Ciccarese C.; Brunelli M.; Santoni M.; Montironi R.; Martignoni G.; Tortora G., Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: ‘Game Over’?, «TARGETED ONCOLOGY», 2016, 11, pp. 431 - 446 [Scientific article]
Ciccarese C; Brunelli M; Montironi R; Fiorentino M; Iacovelli R; Heng D; Tortora G; Massari F., The prospect of precision therapy for renal cell carcinoma., «CANCER TREATMENT REVIEWS», 2016, 49, pp. 37 - 44 [Scientific article]
Ciccarese C.; Di Nunno V.; Montironi R.; Fiorentino M.; Brunelli M.; Tortora G.; Ardizzoni A.; Massari F., The role of precision medicine for the treatment of metastatic renal cell carcinoma, «EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT», 2016, 1, pp. 369 - 377 [Scientific article]
Ciccarese C.; Nobili E.; Grilli D.; Casolari L.; Rihawi K.; Gelsomino F.; Tortora G.; Massari F., The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer, «EXPERT REVIEW OF ANTICANCER THERAPY», 2016, 16, pp. 681 - 696 [Scientific article]
Schepisi G.; Santoni M.; Massari F.; Gurioli G.; Salvi S.; Conteduca V.; Montironi R.; De Giorgi U., Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy, «BIODRUGS», 2016, 30, pp. 263 - 273 [Scientific article]
Ciccarese C.; Massari F.; Tortora G., 2015 and human cancer: Back to overall survival, «FUTURE ONCOLOGY», 2016, 12, pp. 1751 - 1754 [Scientific article]
Ciccarese C.; Massari F.; Tortora G., Acquired hemophagocytic syndrome: Comment to the case report, «FUTURE SCIENCE OA», 2015, 1, Article number: FSO31 , pp. 1 - 4 [Scientific article]
